Young PP, Uzieblo A, Trulock A, et al. Autoantibody formation following alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004;44:67–72.10.1046/j.0041-1132.2003.00589.x14692969
Ayun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37–40.10.1046/j.1537-2995.2002.00007.x11896310
Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086–92.10.1046/j.1537-2995.2001.41091086.x11552063
Cox J, Steane E, Cunningham G, Frenkle E. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485–9.10.1001/archinte.1988.00380110115024
Garratty G. Novel mechanisms for immune destruction of circulating autologous cells. In: Silberstein LE, ed. Autoimmune disorders of blood. Bethesda, MD: American Association of Blood Banks, 1996:79–114.
Salama A, Bhakdi S, Mueller-Eckhardt C. Evidence suggesting the occurrence of C3- independent intravascular immune hemolysis. Reactive hemolysis in vivo. Transfusion 1987;27:49–53.10.1046/j.1537-2995.1987.27187121473.x3810824
Reid ME, Rios M, Powell VI, Pierre C, Malavade V. DNA from blood samples can be used to genotype patients who have recently received a transfusion. Transfusion 2000;40:48–53.10.1046/j.1537-2995.2000.40010048.x10644811
Petz LD, Garraty G. Development of RBC autoantibodies and AIHA following transfusion. In: Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004:335–40.
Naysmith JD, Ortega-Oierres MG, Elson CJ. Rat erythrocyte-induced anti-erythrocyte autoantibody production and control in normal mice. Immunol Rev 1981;55:55–87·10.1111/j.1600-065X.1981.tb00339.x
Lalezari P, Talleyrand NP, Wenz B, et al. Development of direct antiglobulin reaction accompanying alloimmunization in a patient with RhD (D category III) phenotype. Vox Sang 1975;28:19–24.10.1111/j.1423-0410.1975.tb02736.x803741
Argiolu F, Diana G, Arnone M, et al. High-dose intravenous immunoglobulin in the management of autoimmune hemolytic anemia complicating thalassemia major. Acta Haematol 1990;83:65–8.10.1159/0002051702106198